These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 9130306)

  • 21. Cognitive impairment as a target for pharmacological treatment in schizophrenia.
    Davidson M; Keefe RS
    Schizophr Res; 1995 Sep; 17(1):123-9. PubMed ID: 8541245
    [No Abstract]   [Full Text] [Related]  

  • 22. The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia.
    Selva-Vera G; Balanzá-Martínez V; Salazar-Fraile J; Sánchez-Moreno J; Martinez-Aran A; Correa P; Vieta E; Tabarés-Seisdedos R
    BMC Psychiatry; 2010 Jun; 10():47. PubMed ID: 20550658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cognitive deficits in schizophrenia and other psychotic disorders].
    Fagerlund B; Glenthøj BY
    Ugeskr Laeger; 2008 Nov; 170(46):3770-2. PubMed ID: 19014728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of cognitive deficits in schizophrenia.
    Bowie CR; Harvey PD
    Curr Opin Investig Drugs; 2006 Jul; 7(7):608-13. PubMed ID: 16869112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurocognitive impairment in schizophrenia and how it affects treatment options.
    Bilder RM
    Can J Psychiatry; 1997 Apr; 42(3):255-64. PubMed ID: 9114941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cognitive efficacy of atypical antipsychotics in schizophrenia.
    Sharma T; Mockler D
    J Clin Psychopharmacol; 1998 Apr; 18(2 Suppl 1):12S-9S. PubMed ID: 9555611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of risperidone on cognition in patients with schizophrenia.
    Stip E; Lussier I
    Can J Psychiatry; 1996 Oct; 41(8 Suppl 2):S35-40. PubMed ID: 8899249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Viewpoint of schizophrenic patients: a European survey].
    Courtet P
    Encephale; 2001; 27(1):28-38. PubMed ID: 11294036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cognitive differences in schizophrenia on long-term treatments with clozapine, risperidone and typical antipsychotics.
    Han M; Zhang XY; Chen DC; Tan YL; Song CS; Yu YH; Huang XF
    Int Clin Psychopharmacol; 2015 Mar; 30(2):89-95. PubMed ID: 25568968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cognitive and functional effects of atypical antipsychotic medications.
    Harvey PD
    J Clin Psychiatry; 2006 Oct; 67(10):e13. PubMed ID: 17107236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cognitive impairment in schizophrenia.
    Keefe RS; Harvey PD
    Handb Exp Pharmacol; 2012; (213):11-37. PubMed ID: 23027411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cognitive function in schizophrenic patients.
    Tollefson GD
    J Clin Psychiatry; 1996; 57 Suppl 11():31-9. PubMed ID: 8941169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Atypical neuroleptics--the future of schizophrenia treatment?].
    Ebert D
    Fortschr Med; 1998 Jan; 116(3):22-8. PubMed ID: 9522541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia.
    Meltzer HY; Rajagopal L; Huang M; Oyamada Y; Kwon S; Horiguchi M
    Int J Neuropsychopharmacol; 2013 Nov; 16(10):2181-94. PubMed ID: 24099265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacologic strategies for augmenting cognitive performance in schizophrenia.
    Friedman JI; Temporini H; Davis KL
    Biol Psychiatry; 1999 Jan; 45(1):1-16. PubMed ID: 9894570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment.
    Meltzer HY; Thompson PA; Lee MA; Ranjan R
    Neuropsychopharmacology; 1996 Mar; 14(3 Suppl):27S-33S. PubMed ID: 8866741
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book.
    Mishara AL; Goldberg TE
    Biol Psychiatry; 2004 May; 55(10):1013-22. PubMed ID: 15121486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
    Goldberg TE; Goldman RS; Burdick KE; Malhotra AK; Lencz T; Patel RC; Woerner MG; Schooler NR; Kane JM; Robinson DG
    Arch Gen Psychiatry; 2007 Oct; 64(10):1115-22. PubMed ID: 17909123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of cognition in the risk--benefit and safety analysis of antipsychotic medication.
    Borison RL
    Acta Psychiatr Scand Suppl; 1996; 389():5-11. PubMed ID: 8985471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.